(Q50550771)

English

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

scientific article published on 11 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

1 reference

based on heuristic

inferred from title

object named as

Nezam H Afdhal

7

0 references

K. Rajender Reddy

5

object named as

K Rajender Reddy

1 reference

Europe PubMed Central

15 March 2018

3

object named as

Michael P Manns

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

1

object named as

Mark S Sulkowski

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

author name string

Fred Poordad

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Jean-Pierre Bronowicki

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Stephen A Harrison

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Heather L Sings

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Lisa D Pedicone

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Kenneth J Koury

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Vilma Sniukiene

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Margaret H Burroughs

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Janice K Albrecht

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Clifford A Brass

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Ira M Jacobson

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

SPRINT-2 Trial Investigators

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

language of work or name

0 references

publication date

11 February 2013

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

57

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

974-984

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

The natural history of hepatitis C virus (HCV) infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

21 January 2018

A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26096

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26096

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/23081753

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50550771&oldid=1458817105"